Home
NewsNewsMaven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Maven Clinic, the largest virtual clinic specialising in women’s and family health, has announced an expansion of its Fertility and Family Building program. The update introduces earlier diagnostic lab testing, condition-specific care pathways, and the first integration of FDA-listed ovulation prediction insights from ŌURA into a fertility care platform. These enhancements are designed to provide members with answers earlier in their journey and accelerate the transition to appropriate clinical care. The rollout is scheduled to begin this spring, with additional capabilities continuing to launch throughout 2026.
The expansion addresses significant economic and clinical challenges within the fertility sector, where 70% of employers have reported rising costs over the last three years. Despite 85% of infertility cases having identifiable underlying causes, individuals often spend an average of two years attempting to conceive before seeking professional support. This delay frequently results in unnecessary medical interventions and increased emotional stress.
Kate Ryder, founder and CEO of Maven Clinic, stated: "One of the most costly and least visible drivers of waste in our fertility system is delayed diagnosis, months or years spent trying without information, only to arrive at a clinic already behind. Time lost early becomes dollars spent later, in more aggressive treatment, higher-risk pregnancies, and preventable NICU stays. That's why Maven is building fertility care for the future, a connected system where data follows the member, lab diagnostics and wearable technology integrate, care teams cushion decision-making at every juncture and no family starts their journey already feeling like they're failing."
A key component of the updated Fertility and Family Building program is the integration of diagnostic testing directly into the care model. This includes hormone testing, genetic carrier screening, and foundational fertility panels that are typically ordered later in the process. By identifying issues such as hormonal imbalances or ovulatory disorders sooner, members can enter specialist care with established data, reducing delays and avoiding repeat testing. Results are managed within the Maven platform, allowing for direct consultation with providers to determine next steps. Additionally, the program introduces dedicated support for conditions like PCOS—which affects 10–13% of reproductive-age women, as well as endometriosis and oncofertility, the latter in partnership with Color Health.
The program’s technological foundation is powered by Maven Intelligence, an AI-powered orchestration layer that synthesizes data from lab results, clinical inputs, and wearable devices. As part of this strategy, Maven is the first partner to integrate continuous, clinically validated cycle insights from ŌURA to help members and care teams understand optimal timing for conception or when to adjust treatment pathways. These data-driven improvements have already contributed to measurable outcomes: 30% of members achieve pregnancy without assisted reproductive technology, and employers save an average of $9,600 per birth across fertility and maternity care. Furthermore, 88% of members report being more productive at work during their treatment. Future developments for the Fertility and Family Building experience include deeper connectivity with physical clinic partners and the creation of cohort-based insights to improve treatment adherence and support.
INVO Fertility, Inc has confirmed that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network, making advanced reproductive care more widely available and accessible for more patients seeking fertility treatment.
Births resulting from essential Infertility Treatments, including advanced procedures like artificial insemination and IVF, have seen a very positive and promising climb, accounting for almost 15.1% of the total births recorded in 2024.
The Fertility Society of Ghana has urged the government to officially recognize infertility as a disease and include basic fertility services in the National Health Insurance Scheme during its eighth Annual General meeting, held in Tema.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Researchers have developed breakthrough microfluidic technology that can accurately predict how an embryo is going to implant, directly addressing long-standing IVF challenges and offering new hope for improved success rates.
The Florida Supreme Court has clarified that its statute on reproductive technology does not apply to At-Home Artificial Insemination.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
